The global allergy immunotherapy market is projected to grow from USD 3.7 billion in 2025 to USD 5 billion by 2035, registering a CAGR of 3.5%, according to Future Market Insights on 22 May 2025. This growth trajectory reflects the rising global prevalence of allergic diseases and a strong push toward long-term desensitization therapies over symptomatic relief.
Regulatory support in Europe and North America has expanded reimbursement coverage for sublingual and subcutaneous immunotherapies, enabling broader patient access. Notably, in 2024, the European Medicines Agency updated its guidelines on allergen products, streamlining the approval process for recombinant and peptide-based treatments, accelerating market entry for next-gen therapies.
Rising investments in personalized allergy care, alongside AI-powered discovery of novel allergens, are reshaping the treatment landscape. In April 2025, Thermo Fisher Scientific announced advancements in component-resolved diagnostics, stating, “Identifying sensitization patterns at the molecular level allows clinicians to tailor immunotherapy regimens with unprecedented precision.”
In a 2024 position paper, the World Allergy Organization emphasized, “Biologics and oral immunotherapy are poised to redefine treatment norms, especially for food-induced anaphylaxis.” Meanwhile, ALK-Abelló, a leader in allergy solutions, highlighted in its 2025 earnings report, “Sublingual immunotherapy tablets are demonstrating year-on-year double-digit growth across Europe, driven by patient convenience and clinical success.”
Technological progress is centered on improving the safety, duration, and efficacy of therapy. AI integration is streamlining allergen selection and protocol optimization, while recombinant allergen platforms are enabling cleaner and more standardized formulations. These innovations are complemented by a steady pipeline of therapies in late-stage trials, some of which target previously underserved allergies like tree nuts and shellfish. As strategic collaborations between biotech firms and pharma majors increase, the allergy immunotherapy market is shifting toward precision-driven, scalable, and globally accessible care models.
| Metric | Value |
|---|---|
| Global Industry Size (2025E) | USD 3.7 Billion |
| Global Industry Value (2035F) | USD 5 Billion |
| Value-based CAGR (2025 to 2035) | 3.5% |
The Allergy Immunotherapy Market report analyzes various segments including product types such as SLIT tablets, oral immunotherapy, injections, and other product types; immunotherapy approaches including sublingual immunotherapy (SLIT), subcutaneous immunotherapy (allergy shots), and intralymphatic immunotherapy (ILIT); and therapeutic indications such as allergic rhinitis, allergic asthma, food allergy, atopic dermatitis, and other allergy conditions.
Allergen-specific segments covered in the analysis include pollens, house dust mites (HDM), mould, animal dander, bee venom, cockroaches/insects, and other allergen types. Distribution channel analysis includes institutional sales and retail sales, while regional coverage encompasses North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and the Middle East & Africa.
SLIT Tablets are expected to emerge as the most lucrative product segment, with projected revenues reaching USD 2.1 billion by 2035, growing at a CAGR of 4.2%. This growth is driven by rising patient preference for non-invasive treatment and the convenience of self-administration. These tablets have gained regulatory support in Europe and North America for pollen and dust mite allergies and now represent a cornerstone of allergy treatment in outpatient care models. Their safety profile and strong adherence rates further support rapid market expansion.
Oral immunotherapy (OIT) is gaining momentum, particularly in pediatric food allergy management. It is expected to grow at a CAGR of 4.5% and generate revenues of approximately USD 1.2 billion by 2035. The segment is fueled by increasing clinical acceptance of OIT for peanut, milk, and egg allergies. Backed by extensive clinical trials and regulatory approvals, OIT is being integrated into structured desensitization programs across major health systems.
Injections (subcutaneous immunotherapy) remain widely used and are expected to maintain steady growth at a CAGR of 2.7%, reaching USD 1.4 billion by 2035. While less convenient, injections offer long-term remission and are considered highly effective for respiratory allergies. They continue to be the preferred option in specialty allergy clinics and rural areas with limited access to new therapies.
| Product Type Segment | CAGR (2025 to 2035) |
|---|---|
| SLIT Tablets | 4.2% |
Sublingual Immunotherapy (SLIT) is expected to be the most lucrative segment, projected to generate revenues exceeding USD 2.4 billion by 2035, growing at a CAGR of 4.1%. SLIT is gaining widespread traction due to its convenience, non-invasiveness, and strong patient adherence. It is commonly prescribed for allergic rhinitis and grass pollen allergies and has shown excellent safety profiles. Regulatory support in Europe and ongoing FDA approvals in the USA are accelerating its uptake, particularly in pediatric and geriatric populations.
Subcutaneous Immunotherapy (Allergy Shots) continues to maintain strong demand, particularly in North America and parts of Europe, due to its proven long-term efficacy in treating severe allergic conditions. This segment is expected to grow at a CAGR of 3.2%, with estimated revenues reaching USD 1.9 billion by 2035. Allergy shots are favored by allergists for their ability to induce long-lasting desensitization and are increasingly integrated with component-resolved diagnostics for personalized dosing.
| Immunotherapy Type | CAGR (2025 to 2035) |
|---|---|
| Sublingual Immunotherapy (SLIT) | 4.1% |
Allergic Rhinitis remains the most dominant indication, with projected revenues surpassing USD 2.1 billion by 2035, growing at a CAGR of 3.8%. The segment benefits from high global prevalence, especially in urban populations affected by seasonal and perennial allergens. Rising public awareness, along with the availability of convenient therapies like SLIT tablets, has led to widespread adoption across both developed and emerging markets.
Allergic Asthma is projected to grow at a CAGR of 3.5%, generating revenues of around USD 1.1 billion by 2035. Improved diagnostics, coupled with integrated treatment approaches that combine immunotherapy with biologics, are fueling uptake. The segment is also gaining momentum through hospital-based immunotherapy protocols for moderate to severe asthma cases.
Food Allergy treatment is gaining traction, expected to grow at a CAGR of 4.2% to reach approximately USD 870 million by 2035. The increasing incidence of peanut, milk, and egg allergies-especially among children-is encouraging investment in oral immunotherapy and biologic therapies. Regulatory pathways have improved in the USA and EU, encouraging clinical innovations and product launches.
Atopic Dermatitis is forecast to witness moderate growth at a CAGR of 3.1%, achieving market revenues of about USD 600 million by 2035. Although not traditionally addressed by immunotherapy, ongoing research into allergen-specific skin inflammation is opening new therapeutic possibilities, particularly in personalized desensitization programs.
| Indication | CAGR (2025 to 2035) |
|---|---|
| Allergic Rhinitis | 3.8% |
Pollens are expected to remain the leading allergen type, with forecasted revenues of USD 1.7 billion by 2035, growing at a CAGR of 3.7%. This is attributed to the seasonal burden of grass and tree pollens in temperate regions and a strong uptake of SLIT-based therapies targeting these allergens.
House Dust Mites (HDM) are projected to generate USD 1.1 billion in revenues by 2035, with a CAGR of 3.6%. Chronic exposure in household environments and the rise of indoor allergen-related respiratory conditions are driving long-term treatment regimens, particularly in Asia and Western Europe.
Mould Allergens are forecast to grow at a CAGR of 3.3%, reaching USD 680 million by 2035. Rising humidity levels, particularly in subtropical and urbanized regions, have increased clinical presentations of mould-triggered allergies, expanding the need for targeted immunotherapy.
| Allergen Type | CAGR (2025 to 2035) |
|---|---|
| Pollens | 3.7% |
Institutional Sales are expected to remain the dominant distribution channel, projected to generate revenues of approximately USD 3.4 billion by 2035, growing at a CAGR of 3.6%. This growth is supported by high-volume procurement through hospitals, specialized allergy clinics, and academic medical centers.
Institutional settings continue to favor subcutaneous immunotherapy (SCIT) and emerging biologics due to structured treatment protocols and insurance reimbursement frameworks. Increasing investments in public health allergy programs and hospital-based allergy centers are also contributing to sustained growth in this segment.
Retail Sales are forecast to grow at a slightly faster CAGR of 3.9%, with revenues expected to reach USD 1.6 billion by 2035. The segment’s momentum is driven by rising consumer preference for convenience and access to over-the-counter (OTC) or pharmacy-dispensed sublingual immunotherapy (SLIT) tablets.
Retail chains and digital pharmacies are expanding their allergen-specific therapy offerings, especially in developed markets. Direct-to-consumer (DTC) models and e-prescription platforms are further enhancing outreach and adherence, particularly for mild to moderate allergic rhinitis cases managed outside of clinical settings.
| Segment | CAGR (2025 to 2035) |
|---|---|
| Institutional Sales | 3.6% |
| Retail Sales | 3.9% |
The USA allergy immunotherapy market is likely to grow at a CAGR of 3.5%. Three structural forces underpin this trajectory. First, increasing diagnosis rates for allergic rhinitis and food allergies-particularly among pediatric and urban populations-are driving broader adoption of immunotherapeutic interventions.
The Centers for Disease Control and Prevention (CDC) reports a continued rise in allergy-related physician visits, reinforcing demand for long-term treatment alternatives over antihistamines. Second, favorable reimbursement pathways for sublingual immunotherapy (SLIT) and biologics like omalizumab have expanded access across both private and public healthcare plans. Major insurers now include immunotherapy options in standard allergy care bundles, increasing treatment affordability.
Third, innovation from USA-based biopharma companies-including DBV Technologies and Aimmune Therapeutics-has accelerated, with multiple late-stage pipeline assets targeting peanut, tree nut, and pollen allergens. Digital health firms such as Nectar Life Sciences are also pioneering remote SLIT management platforms integrated with AI-based symptom tracking.
The FDA’s progressive stance on accelerated approvals for allergen-specific products, coupled with environmental challenges such as prolonged pollen seasons and rising urban pollution, make the USA a key strategic zone for allergy immunotherapy investment.
| Metric | Value |
|---|---|
| 2025 Value (USD Billion) | 1.12 |
| CAGR 2025 to 2035 | 3.5% |
Germany’s allergy immunotherapy market is projected to register a CAGR of 3.3%. As one of Europe’s most structured and research-intensive healthcare markets, Germany has long been a stronghold for both subcutaneous and sublingual immunotherapy.
The statutory health insurance system (GKV) provides full coverage for approved allergen-specific therapies, enabling wide access across the population. The Robert Koch Institute reports over 25 million Germans suffer from allergy-related conditions, with hay fever and asthma being the most common. This underpins consistent demand for long-term desensitization treatments.
| Metric | Value |
|---|---|
| 2025 Value (USD Billion) | 0.355 |
| CAGR 2025 to 2035 | 3.3% |
The United Kingdom’s allergy immunotherapy market is forecasted to grow at a CAGR of 3.3%. Allergy prevalence in the UK has surged over the past decade, with nearly one in three adults and children affected by conditions such as allergic rhinitis, asthma, and food sensitivities.
The National Health Service (NHS) has gradually increased access to sublingual immunotherapy (SLIT), particularly for grass and tree pollen allergies, through its specialist commissioning programs. However, subcutaneous immunotherapy (SCIT) remains limited to specialist clinics due to the need for supervised administration and emergency preparedness.
| Metric | Value |
|---|---|
| 2025 Value (USD Billion) | 0.231 |
| CAGR 2025 to 2035 | 3.3% |
France’s allergy immunotherapy market is set to grow at a CAGR of 3.4%. With over 30% of the population affected by allergic conditions, France maintains a robust immunotherapy ecosystem supported by a highly structured healthcare framework. The Assurance Maladie (public health insurance) provides broad reimbursement for allergen-specific immunotherapies, particularly SCIT for pollens, mites, and animal dander. Sublingual immunotherapy (SLIT) is also gaining popularity due to improved patient adherence and at-home convenience.
France has a longstanding tradition of allergy research, with Institut Pasteur and AP-HP hospitals contributing significantly to clinical studies on recombinant allergens and personalized therapy. In 2024, the French Ministry of Health updated its allergy treatment guidelines, promoting early immunotherapeutic intervention in pediatric patients and encouraging digital tracking tools for symptom monitoring. Companies like Stallergenes Greer and Lallemand Pharma are leading domestic innovation in allergen extract formulations and pediatric delivery systems.
Environmental triggers such as urban air pollution and prolonged pollen seasons continue to drive incidence rates. While awareness is high, regional differences in specialist access and slower SLIT adoption in rural areas present challenges. Nonetheless, France remains a high-impact market with stable reimbursement and clinical innovation.
| Metric | Value |
|---|---|
| 2025 Value (USD Billion) | 0.296 |
| CAGR 2025 to 2035 | 3.4% |
Japan’s allergy immunotherapy market is likely to advance at a CAGR of 3.5%. Allergic rhinitis-particularly triggered by cedar pollen-is a major health concern in Japan, affecting over 40% of the population. The Ministry of Health, Labour and Welfare (MHLW) has prioritized allergy control through national campaigns, leading to expanded access to sublingual immunotherapy (SLIT), especially in urban centers like Tokyo and Osaka. SCIT is also available, though it is prescribed less frequently due to clinic-visit constraints and patient preference for at-home therapy.
Japanese pharmaceutical companies such as Torii Pharmaceutical and Mitsubishi Tanabe Pharma are at the forefront of allergen-specific drug development. In 2024, Japan became one of the first countries in Asia to approve SLIT tablets for house dust mite and Japanese cedar allergens for children, following favorable safety and efficacy data. The integration of AI-powered tools for allergy symptom tracking and adherence monitoring is gaining momentum through health-tech partnerships.
Despite Japan’s aging population, youth allergy diagnosis rates are climbing, supported by school-based screenings. While treatment adherence remains a challenge, high awareness, government support, and technological integration position Japan as a progressive market for allergy immunotherapy.
| Metric | Value |
|---|---|
| 2025 Value (USD Billion) | 0.298 |
| CAGR 2025 to 2035 | 3.5% |
China’s allergy immunotherapy market is likely to grow at a CAGR of 3.6%. Rising urbanization, increased pollution, and changes in dietary and lifestyle habits have contributed to a significant uptick in allergic diseases-particularly allergic rhinitis and food allergies-in both pediatric and adult populations. The Chinese National Health Commission has recognized this public health concern, resulting in increased support for early diagnosis and long-term treatment solutions, including immunotherapy.
While the market is still dominated by antihistamines and corticosteroids, there is a marked shift toward allergen-specific treatments in Tier 1 and Tier 2 cities. Local companies, including CSPC Pharmaceutical and Beijing Hanmi Pharmaceutical, are partnering with academic institutions to develop regionally relevant allergen extracts, including mugwort, cockroach allergens, and common food triggers. Regulatory reform by the National Medical Products Administration (NMPA) is gradually opening pathways for domestic SLIT and SCIT product approvals.
China’s strong digital healthcare infrastructure is accelerating SLIT adoption via online prescription platforms and remote monitoring apps. However, disparities in allergy specialist availability and limited immunotherapy access in rural provinces remain key obstacles. As public health awareness increases, China is poised to become a major growth engine for allergy immunotherapy in Asia.
| Metric | Value |
|---|---|
| 2025 Value (USD Billion) | 0.402 |
| CAGR 2025 to 2035 | 3.6% |
India’s allergy immunotherapy market is set to grow at a CAGR of 3.9%. Rapid urbanization, increasing vehicular pollution, and shifting dietary habits are contributing to a rising incidence of allergic rhinitis, asthma, and food allergies, particularly in pediatric and adolescent populations. Despite low per capita healthcare spending, awareness around allergy diagnostics and long-term management is steadily improving, especially in metro cities like Delhi, Mumbai, and Bengaluru.
The Indian market has historically been underpenetrated in terms of allergen-specific therapies, but this is changing with growing interest in both subcutaneous (SCIT) and sublingual immunotherapy (SLIT). Indian firms such as Alkem Laboratories and Merck India have initiated the development and localized distribution of allergen extracts tailored to regional triggers like Parthenium, house dust mites, and cockroach allergens. While SCIT remains dominant in hospital settings, SLIT is gaining acceptance due to its at-home convenience and fewer clinic visits.
Lack of regulatory harmonization and limited specialist infrastructure outside Tier 1 cities pose significant challenges. However, government-backed digital health missions and telemedicine platforms are beginning to bridge the urban-rural treatment divide. India represents a high-growth frontier with vast untapped potential for scalable allergy immunotherapy solutions.
| Metric | Value |
|---|---|
| 2025 Value (USD Billion) | 0.267 |
| CAGR 2025 to 2035 | 3.9% |
| Company Name | Estimated Market Share (%) |
|---|---|
| ALK Abelló | 18-22% |
| Stallergenes Greer | 15-18% |
| Allergy Therapeutics | 11-14% |
| HAL Allergy Group | 9-12% |
ALK Abelló leads the global allergy immunotherapy landscape with an estimated market share of 18-22%, owing to its expansive SLIT tablet portfolio and strong clinical pipeline targeting common respiratory allergens. Its focus on improving patient adherence and expanding pediatric formulations has solidified its position across Europe and North America.
Stallergenes Greer follows with a market share of 15-18%, leveraging its dual manufacturing base and allergen-specific immunotherapy expertise. The company’s growth is propelled by its high-purity extracts and established relationships with specialist allergists.
Allergy Therapeutics holds a market share of 11-14% and is recognized for its ultra-short-course SCIT programs and continued investment in recombinant allergen technologies. HAL Allergy Group commands approximately 9-12% of the market by focusing on tailored treatment options and integrated diagnostics in allergy clinics throughout Europe. Biomay AG maintains a niche share of 7-10%, specializing in GMP-grade allergen production and contract manufacturing for clinical trial partners.
HollisterStier Allergy secures a 6-9% market share through its USA-centric operations, offering bulk extracts and customized allergen vials for specialist practices. Desentum OY and Anergis are emerging players, collectively accounting for 4-7% market share with their peptide-based and hypoallergenic vaccine innovations.
DBV Technologies and Roche are making strategic inroads into food allergy immunotherapy, particularly for pediatric use. Dermapharm Holdings, via subsidiary operations, contributes 2-4% through licensed SLIT solutions. The remaining 12-15% of the market is distributed among regional producers and academic manufacturers classified under "Others".
| Report Attributes | Details |
|---|---|
| Current Total Market Size (2025) | USD 3.7 billion |
| Projected Market Size (2035) | USD 5 billion |
| CAGR (2025 to 2035) | 3.5% |
| Base Year for Estimation | 2024 |
| Historical Period | 2020 to 2024 |
| Projections Period | 2025 to 2035 |
| Market Analysis Parameters | Revenue in USD billion |
| By Product Type | SLIT Tablets, Oral, Injections, Other Product Types |
| By Immunotherapy Type | Sublingual Immunotherapy (SLIT), Subcutaneous Immunotherapy (Allergy Shots), Intralymphatic Immunotherapy (ILIT) |
| By Indication | Allergic Rhinitis, Allergic Asthma, Food Allergy, Atopic Dermatitis, Other Indications |
| By Allergen Type | Pollens, House Dust Mites (HDM), Mould, Animal Dander, Bee Venom, Cockroaches/Insects, Other Allergen Types |
| By Distribution Channel | Institutional Sales, Retail Sales |
| Regions Covered | North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa |
| Countries Covered | United States, Canada, Germany, United Kingdom, France, China, India, Japan, Brazil, Australia |
| Key Players | ALK Abelló , Stallergenes Greer, Allergy Therapeutics, HAL Allergy Group, Biomay AG, HollisterStier Allergy, Desentum OY, Anergis , DBV Technologies, Roche, Dermapharm Holdings |
| Additional Attributes | Dollar sales by value, market share analysis by company, region-wise and country-wise performance metrics |
The market is segmented into SLIT Tablets, Oral, Injections, and Other Product Types.
The market is categorized into Sublingual Immunotherapy (SLIT), Subcutaneous Immunotherapy (Allergy Shots), and Intralymphatic Immunotherapy (ILIT).
The market is segmented into Allergic Rhinitis, Allergic Asthma, Food Allergy, Atopic Dermatitis, and Other Indications.
The market is divided into Pollens, House Dust Mites (HDM), Mould, Animal Dander, Bee Venom, Cockroaches/Insects, and Other Allergen Types.
The market is segmented into Institutional Sales and Retail Sales.
The market is categorized into North America, Latin America, East Asia, South Asia and Pacific, Western Europe, Eastern Europe, and Middle East and Africa.
The Allergy Immunotherapy allergy immunotherapy industry is projected to reach USD 3.7 billion in 2025.
Demand is anticipated to climb to USD 5 billion by 2035, reflecting steady expansion across regions.
The industry is forecast to grow at a compound annual growth rate (CAGR) of 3.5% over the forecast period.
Allergic rhinitis remains the most commonly treated condition with immunotherapy, especially in urban populations.
Notable companies include ALK Abelló, Stallergenes Greer, Allergy Therapeutics, HAL Allergy Group, and DBV Technologies.
Explore Therapy Area Insights
Allergy Immunotherapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
